Can Alnylam Pharmaceuticals, Inc. (ALNY)’s Tomorrow be Different? The Stock Just Broke Its High

June 20, 2017 - By Louis Casey

Investors sentiment decreased to 0.77 in 2016 Q4. Its down 0.25, from 1.02 in 2016Q3. It turned negative, as 64 investors sold Alnylam Pharmaceuticals, Inc. shares while 65 reduced holdings. 35 funds opened positions while 64 raised stakes. 78.05 million shares or 3.80% more from 75.19 million shares in 2016Q3 were reported.
Retail Bank Of America De invested in 0% or 46,964 shares. Jane Street Gp Lc reported 44,616 shares or 0.01% of all its holdings. Oxford Asset accumulated 19,723 shares. Glenmede Na holds 175 shares or 0% of its portfolio. Sg Americas Securities Limited Liability Co reported 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Blackrock Advsrs Ltd Limited Liability Company, Delaware-based fund reported 43,922 shares. Rhenman And Asset Mgmt Ab reported 135,000 shares. Bnp Paribas Arbitrage invested in 15,771 shares. State Of Wisconsin Inv Board invested 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Pnc Finance Svcs invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Frontier Capital Mngmt Ltd Llc accumulated 0.07% or 236,935 shares. Guggenheim Ltd Limited Liability Company owns 79,083 shares for 0.01% of their portfolio. Utd Svcs Automobile Association holds 0% or 27,190 shares. Commonwealth Equity Serv invested in 6,584 shares. Da Davidson & Com has 140 shares for 0% of their portfolio.

Since January 18, 2017, it had 2 insider purchases, and 6 insider sales for $15.68 million activity. The insider SHARP PHILIP A sold 15,000 shares worth $569,250. Vaishnaw Akshay had sold 11,000 shares worth $825,000 on Tuesday, May 23. Mason Michael had sold 9,375 shares worth $656,250. 297,501 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares with value of $21.38M were bought by Sanofi. KEATING LAURIE bought $751,502 worth of stock.

The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) hit a new 52-week high and has $84.57 target or 4.00 % above today’s $81.32 share price. The 5 months bullish chart indicates low risk for the $7.73B company. The 1-year high was reported on Jun, 20 by Barchart.com. If the $84.57 price target is reached, the company will be worth $309.20M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

About 63,395 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since June 20, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 16 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 9 have Buy rating, 0 Sell and 7 Hold. Therefore 56% are positive. Alnylam Pharmaceuticals has $184 highest and $34 lowest target. $79.73’s average target is -1.96% below currents $81.32 stock price. Alnylam Pharmaceuticals had 35 analyst reports since August 7, 2015 according to SRatingsIntel. Goldman Sachs maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, October 6. Goldman Sachs has “Neutral” rating and $34 target. The company was downgraded on Thursday, October 6 by JP Morgan. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Thursday, October 6 by Needham. On Thursday, October 6 the stock rating was maintained by Jefferies with “Buy”. Stifel Nicolaus maintained the shares of ALNY in report on Thursday, October 6 with “Hold” rating. The stock has “Buy” rating by Ladenburg Thalmann on Thursday, February 2. Leerink Swann maintained the shares of ALNY in report on Tuesday, May 3 with “Outperform” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by Credit Suisse on Wednesday, January 20. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by Credit Suisse on Thursday, October 6. The firm earned “Outperform” rating on Tuesday, February 16 by Leerink Swann.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Businesswire.com which released: “Alnylam Pharmaceuticals Prices Public Offering of Common Stock” on May 24, 2017, also Nasdaq.com with their article: “Commit To Buy Alnylam Pharmaceuticals At $50, Earn 18% Annualized Using Options” published on May 26, 2017, Zacks.com published: “Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline” on May 25, 2017. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Businesswire.com and their article: “Alnylam Significantly Expands Patent Portfolio with New Allowances from United …” published on June 12, 2017 as well as Prnewswire.com‘s news article titled: “Stocks Under Scanner in the Biotech Space — Paratek Pharma, Verastem, Alnylam …” with publication date: June 07, 2017.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $7.73 billion. The Firm is engaged in the discovery, development and commercialization of ribonucleic acid interference (RNAi) therapeutics. It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.